$21.93
1.06%
Nasdaq, Jan 02, 10:11 pm CET
ISIN
BMG762791017
Symbol
ROIV

Roivant Sciences Stock price

$21.93
+1.83 9.10% 1M
+10.96 99.91% 6M
+0.23 1.06% YTD
+9.85 81.54% 1Y
+13.94 174.47% 3Y
+11.75 115.42% 5Y
+12.01 121.07% 10Y
+12.01 121.07% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.23 1.06%
ISIN
BMG762791017
Symbol
ROIV
Industry

Key metrics

Basic
Market capitalization
$15.3b
Enterprise Value
$10.9b
Net debt
positive
Cash
$4.4b
Shares outstanding
689.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
750.2 | 798.0
EV/Sales
534.5 | 568.5
EV/FCF
negative
P/B
3.5
Financial Health
Equity Ratio
86.2%
Return on Equity
-3.7%
ROCE
-23.3%
ROIC
-181.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$20.3m | $19.1m
EBITDA
$-1.1b | $-1.2b
EBIT
$-1.2b | $-1.2b
Net Income
$-374.0m | $-885.0m
Free Cash Flow
$-784.4m
Growth (TTM | estimate)
Revenue
-74.1% | -34.2%
EBITDA
-5.2% | -9.4%
EBIT
-3.8% | -8.2%
Net Income
-107.8% | -414.6%
Free Cash Flow
-0.4%
Margin (TTM | estimate)
Gross
96.4%
EBITDA
-5,628.1% | -6,291.3%
EBIT
-5,659.4%
Net
-1,839.6% | -4,630.3%
Free Cash Flow
-3,858.5%
More
EPS
$-0.5
FCF per Share
$-1.1
Short interest
3.4%
Employees
750
Rev per Employee
$40.0k
Show more

Is Roivant Sciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Roivant Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Roivant Sciences forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Roivant Sciences forecast:

Buy
89%
Hold
11%

Financial data from Roivant Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
20 20
74% 74%
100%
- Direct Costs 0.73 0.73
91% 91%
4%
20 20
72% 72%
96%
- Selling and Administrative Expenses 566 566
16% 16%
2,783%
- Research and Development Expense 604 604
19% 19%
2,973%
-1,144 -1,144
5% 5%
-5,628%
- Depreciation and Amortization 6.37 6.37
69% 69%
31%
EBIT (Operating Income) EBIT -1,151 -1,151
4% 4%
-5,659%
Net Profit -374 -374
108% 108%
-1,839%

In millions USD.

Don't miss a Thing! We will send you all news about Roivant Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roivant Sciences Stock News

Neutral
Seeking Alpha
13 days ago
The Goldman Sachs Mid Cap Growth Fund underperformed its benchmark, the Russell Midcap Growth Index (net), during the quarter. United Rentals, Inc. released a positive quarterly earnings report, surpassing earnings expectations and raising future guidance, which the street responded favorably toward. Roivant Sciences Ltd.'s stock price soared during the period following the release of positive ...
Neutral
Seeking Alpha
23 days ago
Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript
Neutral
GlobeNewsWire
25 days ago
BASEL, Switzerland and LONDON and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today is hosting an Investor Day in New York City. Roivant leadership will highlight key pipeline updates and provide an update on the Company's strategy for long-term value creation.
More Roivant Sciences News

Company Profile

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Head office Bermuda
CEO Matthew Gline
Employees 750
Founded 2014
Website roivant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today